Imugene has received approval from Western Institutional Review Board to commence Phase I clinical trial of its VAXINIA.
The US component of the Stage I trial will be done under the FDA investigational new drug (IND) process.
The clinical trial is expected to run for 2 years, and will be financed from the current budget and resources.
On 23 March 2022, Imugene shares are trading up on ASX following the announcement about the commencement of Phase I clinical trial of its oncolytic virotherapy candidate, VAXINIA, in multiple solid tumors in patients. It has received approval from Western Institutional Review Board (WIRB).
At AEDT 3:38 PM, IMU shares are trading at AU$0.285, up 9.615% from the previous close.
Imugene (ASX:IMU) shares up on ASX Here’s why?
Key Takeaways:
On 23 March 2022, Imugene shares are trading up on ASX following the announcement about the commencement of Phase I clinical trial of its oncolytic virotherapy candidate, VAXINIA, in multiple solid tumors in patients. It has received approval from Western Institutional Review Board (WIRB).
At AEDT 3:38 PM, IMU shares are trading at AU$0.285, up 9.615% from the previous close.
Recent Latest News